The last decade has witnessed a fundamental rethinking of the traditional concept of tumor-immune evasion. From the sole actor fighting host immune cells, tumor is now being seen as an entity deviously hijacking host immunoregulatory cells to create an immunoprivileged niche. Different players have been identified among this class of cells that, depending on the need to be activated by an antigen receptor, can be classified into effectors of adaptive or innate tolerance. Regulatory T cells (T_(regs)) are probably the most studied in the first category, and their presence has been extensively documented in solid and hematologic malignancies, in which they are associated with a worse clinical outcome. More recently, B-cell regulatory subsets have also been observed in neoplastic conditions.
展开▼
